Novo Holdings participates in series B round at Belgian cancer firm

Biotech company Precirix raises EUR 80m from a consortium of investors, which included Novo Holdings.
Photo: Novo Holdings / PR
Photo: Novo Holdings / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Belgian biotech firm Precirix has finished a series B financing round raising EUR 80m, a press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading